A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.
Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021.
Sutent, which is approved for use in advanced kidney cancer, gastrointestinal and pancreatic tumors, raked in sales of about $578 million in the first half of this year.
The case is Pfizer Inc v. Mylan Pharmaceuticals Inc, U.S. District Court, District of Delaware, No. 10-cv-00528-GMS.
